NCT00560430

Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Ludwig-Maximilians - University of Munich · Academic / Other
• Sex: All
• Age: 19 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

A number of studies have shown that certain blood-pressure medications such as ACE-inhibitors and angiotensin-II-receptor blockers (ARB) can reduce the incidence of diabetes mellitus type 2. This protocol will evaluate whether inflammatory mechanisms mediate this effect. The investigators therefore will investigate the effect of telmisartan, a potent ARB, on lipid metabolism, glucose metabolism and inflammation in patients with the metabolic syndrome. Specific parameters will be tested before treatment and after 3 months of treatment. Placebo will be compared to 2 different doses of telmisartan per day.

Conditions

• Hypertension
• Metabolic Syndrome
• Hypertriglyceridemia

Interventions

Type	Name	Description
DRUG	telmisartan	80 mg per day, orally, weeks 1-14
DRUG	telmisartan	80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
DRUG	placebo	placebo; orally weeks 1-14

Timeline

• Start date: 2007-11-01
• Primary completion: 2009-09-01
• Completion: 2009-10-01
• First posted: 2007-11-19
• Last updated: 2010-07-15

Locations

2 sites across 1 country: Germany